CELIRECO19.: Investigation of the function of innate lymphoid cells (ILC) in the protection of renal complications in COVID-19 patients (Q2867196)
Jump to navigation
Jump to search
Project Q2867196 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CELIRECO19.: Investigation of the function of innate lymphoid cells (ILC) in the protection of renal complications in COVID-19 patients |
Project Q2867196 in Portugal |
Statements
492,223.0 Euro
0 references
499,557.0 Euro
0 references
98.53 percent
0 references
1 April 2020
0 references
31 December 2020
0 references
LIMM THERAPEUTICS, SOCIEDADE ANÓNIMA
0 references
40°21'55.76"N, 8°39'29.95"W
0 references
O projeto apresentado pela LiMM Therapeutics pretende avaliar a possibilidade de desenvolvimento de NRIL01 (reprogramadores neuronais de linfócitos inatos) na presença de SARS-CoV-2, contribuindo desta forma para minimizar as patologias renais como consequência da infeção com este vírus. (Portuguese)
0 references
The project presented by LIMM Therapeutics aims to evaluate the possibility of developing NRIL01 (neurnal reprogrammers of innate lymphocytes) in the presence of SARS-CoV-2, thus contributing to minimising renal pathologies as a consequence of infection with this virus. (English)
7 July 2021
0 references
Le projet présenté par LIMM Therapeutics vise à évaluer la possibilité de développer NRIL01 (reprogrammeurs neuronaux de lymphocytes innés) en présence de SARS-CoV-2, contribuant ainsi à minimiser les pathologies rénales résultant de l’infection par ce virus. (French)
4 December 2021
0 references
Das von LIMM Therapeutics vorgestellte Projekt zielt darauf ab, die Möglichkeit der Entwicklung von NRIL01 (neurale Reprogrammierer von angeborenen Lymphozyten) in Gegenwart von SARS-CoV-2 zu bewerten und so zur Minimierung der Nierenpathologien als Folge einer Infektion mit diesem Virus beizutragen. (German)
13 December 2021
0 references
Het door LIMM Therapeutics gepresenteerde project heeft tot doel de mogelijkheid te evalueren om NRIL01 (neurale herprogrammeurs van aangeboren lymfocyten) te ontwikkelen in aanwezigheid van SARS-CoV-2, en zo bij te dragen aan het minimaliseren van nierpathologieën als gevolg van infectie met dit virus. (Dutch)
18 December 2021
0 references
Il progetto presentato da LIMM Therapeutics mira a valutare la possibilità di sviluppare NRIL01 (riprogrammatori neurali di linfociti innati) in presenza di SARS-CoV-2, contribuendo così a ridurre al minimo le patologie renali come conseguenza dell'infezione da questo virus. (Italian)
17 January 2022
0 references
Cantanhede
0 references
Identifiers
CENTRO-01-02B7-FEDER-069917
0 references